Evidence map›Paper›PMID 26459009›Full record

ArticleMolecular medicine reports2015

Downregulation of P-gp, Ras and p-ERK1/2 contributes to the arsenic trioxide-induced reduction in drug resistance towards doxorubicin in gastric cancer cell lines.

Yuan-Yuan Zhao, Li Yu, Bao-Ling Liu, Xin-Jia He, Bi-Yuan Zhang

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular medicine reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. ERK is a Pivotal Player of Chemo-Immune-Resistance in Cancer.International journal of molecular sciences · 2019
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yuan-Yuan ZhaoDepartment of Oncology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong 266000, P.R. China.
Li YuDepartment of Oncology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong 266000, P.R. China.
Bao-Ling LiuDepartment of Oncology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong 266000, P.R. China.
Xin-Jia HeDepartment of Oncology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong 266000, P.R. China.
Bi-Yuan ZhangDepartment of Oncology, The Affiliated Hospital of Medical College, Qingdao University, Qingdao, Shandong 266000, P.R. China.
Qingdao University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance (MDR) to doxorubicin (DOX) limits its effectiveness against tumor cells. Arsenic trioxide (As2O3) has been reported to reduce MDR in various types of cancer, but the mechanisms involving Ras and p-glycoprotein (P-gp) remain to be fully elucidated. The objectives of the present study were to evaluate As2O3 in reversing MDR to DOX, and to identify the association in antitumor activities between the effectiveness of DOX and Ras/phosphorylated (p‑) extracellular signal‑regulated kinase (ERK)1/2 signaling in SGC7901/ADM and SGC7901/S human gastric cancer cell lines. Cytotoxicity and sensitivity towards As2O3 were assessed using non‑toxic and mildly‑toxic concentrations (0.1 and 0.5 µM, respectively). The reversing effect of As2O3 on MDR was investigated prior to and following treatment with a cytokine activation of the recombinant human granulocyte colony stimulating factor ERK pathway. The SGC7901/ADM and SGC7901/S cells had the same sensitivity to As2O3. The SGC7901/ADM cells were resistant to DOX and As2O3 treatment reduced the level of resistance to DOX (P<0.01). The expression of P‑glycoprotein (P-gp) in the SGC7901/ADM cells was higher than in the SGC7901/S cells (P<0.001). As2O3 treatment decreased the levels of P‑gp in a time‑ and dose‑dependent manner (P<0.01). The expression of Ras was higher in the SGC7901/ADM cells than in the SGC7901/S cells, while the expression of p‑ERK1/2 remained the same. As2O3 decreased the levels of Ras and p‑ERK1/2 (P<0.01). Following pretreatment with rhG‑CSF, the levels of Ras and p‑ERK1/2 were further decreased (P<0.01). Drug‑resistant gastric cancer cells had higher expression levels of P‑gp and Ras, but not of p‑ERK1/2. Non‑ and mildly‑toxic doses of As2O3 reduced MDR to DOX through Ras/p-ERK1/2 signaling.

Indexed as

Antineoplastic AgentsArsenicalsArsenic TrioxideATP Binding Cassette Transporter, Subfamily B, Member 1Cell Line, TumorDown-RegulationDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmGastric MucosaHumansMAP Kinase Signaling SystemOxidesras ProteinsStomachStomach NeoplasmsAntineoplastic AgentsArsenicalsArsenic TrioxideATP Binding Cassette Transporter, Subfamily B, Member 1DoxorubicinOxidesras Proteins

Identifiers

PMID26459009
PMCPMC4626124
OpenAlexW2159185818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.